Publications by authors named "Michael Blue"

Claim this Profile
U
Utility of [Tc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility study.
Sarah Boughdad, Sofiya Latifyan, Margret Schottelius, Michael Blue, Stéphanie Tissot

Cancer Immunol Immunother· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to the inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach [Nucl Med Biol 43 (2016) 215-225].
Frederick O Cope, Bonnie Abbruzzese, James Sanders, Wendy Metz, Kristyn Sturms, Michael Blue

Nucl Med Biol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.
Frederick O Cope, Bonnie Abbruzzese, James Sanders, Wendy Metz, Kristyn Sturms, Michael Blue

Nucl Med Biol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).
Abul K Azad, Murugesan V S Rajaram, Wendy L Metz, Frederick O Cope, Michael S Blue

J Immunol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.
Christopher A Tokin, Frederick O Cope, Wendy L Metz, Michael S Blue, Beth M Potter

Clin Exp Metastasis· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis